Semi-Solid Dosage Contract Manufacturing Market Future Outlook: Strong Growth Expected Toward $29.52 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the semi-solid dosage contract manufacturing market from 2026–2035 with trusted insights from The Business Research Company
By how much is the Semi-Solid Dosage Contract Manufacturing Market expected to grow between 2026 and 2030?
The semi-solid dosage contract manufacturing market size has experienced rapid expansion over recent years. This market is projected to advance from $17.97 billion in 2025 to $19.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historic period can be primarily attributed to factors such as the increasing complexity within the pharmaceutical pipeline, rising cost pressures impacting in-house manufacturing, the expanding use of topical and transdermal drug formulations, a growing demand for contract manufacturing services, and the availability of specialized cmo capabilities.
The semi-solid dosage contract manufacturing market is projected to experience substantial expansion in the coming years, reaching a valuation of $29.52 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.4%. This anticipated growth during the forecast period is fueled by several factors, including a heightened demand for customized topical treatments, increased capital allocation towards innovative formulation techniques, the broadening scope of cosmeceutical outsourcing, a greater emphasis on using sustainable excipients, and intensified regulatory oversight concerning manufacturing standards. Key developments anticipated in this period encompass a rise in the outsourcing of semi-solid drug production, an escalating need for specialized dermatological preparations, wider integration of adaptable manufacturing processes, the proliferation of bio-based and natural formulation options, and a reinforced commitment to production methods that meet regulatory requirements.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25899&type=smp
Which Drivers Are Influencing Market Acceleration In The Semi-Solid Dosage Contract Manufacturing Market?
The increasing occurrence of skin conditions is projected to stimulate the expansion of the semi-solid dosage contract manufacturing market in the future. These disorders involve conditions impacting the skin’s appearance or operation, frequently leading to signs like irritation, inflammation, or unusual skin growths. A rise in environmental pollution contributes to the increase in skin ailments, as it compromises the skin’s protective barrier, resulting in heightened sensitivity, allergic responses, and ongoing dermatological issues. The contract manufacturing of semi-solid dosage forms aids in preventing skin diseases through the provision of superior, consistently formulated topical treatments that effectively preserve and enhance skin wellness. For example, data from February 2023 by Cancer Research UK, a UK-based cancer research organization, indicates that the average annual incidence of melanoma skin cancer in the UK is predicted to increase from approximately 20,800 cases between 2023–2025 to about 26,500 cases by 2038–2040. Consequently, the widespread occurrence of skin conditions is a key factor propelling the expansion of the semi-solid dosage contract manufacturing market.
What Segments Are Identified Within The Structure Of The Semi-Solid Dosage Contract Manufacturing Market?
The semi-solid dosage contract manufacturing market covered in this report is segmented –
1) By Type: Topical, Transdermal, Oral
2) By Material Type: Synthetic, Natural, Bio-Based
3) By Company Size: Large Size Companies, Medium And Small Size Companies
4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications
5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses
Subsegments:
1) By Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams
2) By Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches
3) By Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies
What Trends Are Projected To Support The Growth Of The Semi-Solid Dosage Contract Manufacturing Market?
Major companies operating in the semi-solid dosage contract manufacturing market are emphasizing strategic investments to enter new markets and drive innovative solutions. Strategic investments are defined as long-term financial commitments made to support and strengthen a company’s core objectives, future growth, or competitive position. For example, in March 2025, LGM Pharma, a US-based provider of semi-solid dosage contract manufacturing services, declared an investment exceeding $6 million to expand its manufacturing plant in Rosenberg, Texas. This investment aims to significantly enhance production capacity for liquid, suspension, semi-solid, and suppository drug formulations to address the rising demand for domestic pharmaceutical manufacturing. This initiative aligns with LGM Pharma’s ongoing expansion in prescription drug development, including 505(b)(2) and ANDA programs. The upgrades at the Rosenberg site will enable increased output while ensuring full compliance with FDA requirements and current good manufacturing practices. The facility is expected to maintain continuous operation during the expansion period.
Which Key Market Players Are Investing In Expansion And Innovation Within The Semi-Solid Dosage Contract Manufacturing Market?
Major companies operating in the semi-solid dosage contract manufacturing market are The Lubrizol Corporation, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, ANI Pharmaceuticals, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science, Tergus Pharma, MedPharm Ltd., Alcami Corporation
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Semi-Solid Dosage Contract Manufacturing Market?
North America was the largest region in the semi-solid dosage contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semi-solid dosage contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Semi-Solid Dosage Contract Manufacturing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25899&type=smp
Browse Through More Reports Similar to the Global Semi-Solid Dosage Contract Manufacturing Market 2026, By The Business Research Company
Pharmaceutical Continuous Manufacturing Market Report 2026
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Fill Finish Pharmaceutical Contract Manufacturing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
